Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenue $ 3,891 $ 5,697 $ 15,634 $ 15,686
Operating expenses:        
Research and development 25,759 27,262 84,030 73,077
General and administrative 8,076 5,346 21,970 16,606
Transaction related expenses 9,510   9,510  
Total operating expenses 43,345 32,608 115,510 89,683
Loss from operations (39,454) (26,911) (99,876) (73,997)
Interest income 392 32 539 56
Interest expense (1,051) (984) (3,008) (2,921)
Change in fair value of warrant liability 9,860 1,836 12,465 14,117
Net loss applicable to common stockholders $ (30,253) $ (26,027) $ (89,880) $ (62,745)
Net loss per share applicable to common stockholders - basic $ (3.21) $ (4.14) $ (11.93) $ (10.06)
Net loss per share applicable to common stockholders - diluted $ (3.21) $ (4.14) $ (11.93) $ (10.06)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic 9,417,069 6,292,830 7,536,149 6,239,482
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted 9,417,069 6,292,830 7,536,149 6,239,482